Literature DB >> 19944886

Management of schizophrenia with substance use disorders.

Janice Lybrand1, Stanley Caroff.   

Abstract

Around 50% of patients with schizophrenia develop a co-occurring substance use disorder involving alcohol or illicit substances at some time during their lives. The comorbid substance abuse will markedly affect the course of illness of schizophrenia. In this article, the authors review the epidemiology, theories of causation, effect on the course of illness, and treatment of co-occurring schizophrenia and substance use disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944886     DOI: 10.1016/j.psc.2009.09.002

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  5 in total

1.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

Review 2.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 3.  Cannabis Use Among Patients With Psychotic Disorders.

Authors:  Matthew E Hirschtritt; Kelly C Young-Wolff; Daniel H Mathalon; Derek D Satre
Journal:  Perm J       Date:  2021-05-12

4.  Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.

Authors:  Nanna Gilliam Toftdahl; Merete Nordentoft; Carsten Hjorthøj
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-08-11       Impact factor: 4.328

Review 5.  Assessment of clinical co-morbidities.

Authors:  Debasish Basu; Aniruddha Basu; Abhishek Ghosh
Journal:  Indian J Psychiatry       Date:  2018-02       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.